½ÃÀ庸°í¼­
»óǰÄÚµå
1762531

ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish Á¦Á¶ ½ÃÀå : ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø - Ä¡·á ¿µ¿ªº°, ½Ã¸°Áö ¹è·² ÀçÁúº°, ¾àÁ¦ ºÐÀÚº°, »ç¾÷ ±Ô¸ðº°, ÁÖ¿ä Áö¿ªº°

Prefilled Syringe Fill Finish Manufacturing Market: Industry Trends and Global Forecasts - Distribution by Type of Therapeutic Area, Type of Syringe Barrel Material, Type of Drug Molecule, Scale of Operation and Key Geographical Regions

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Roots Analysis | ÆäÀÌÁö Á¤º¸: ¿µ¹® 267 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish Á¦Á¶ ½ÃÀå : °³¿ä

¼¼°èÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish Á¦Á¶ ½ÃÀå ±Ô¸ð´Â ¿ÃÇØ 9¾ï 3,100¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¿¹Ãø ±â°£ Áß 11.9%ÀÇ À¯¸®ÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ±Ô¸ð ¹× ±âȸ ºÐ¼®Àº ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö¿¡ °ÉÃÄ ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù.

Ä¡·á ¿µ¿ª

  • Ç÷¾× Áúȯ
  • °¨¿°¼º Áúȯ
  • ´ë»ç¼º Áúȯ
  • Á¾¾ç Áúȯ
  • ½Å°æÁúȯ
  • ÀÚ°¡¸é¿ªÁúȯ
  • ±âŸ

ÁÖ»ç±â ¹è·² ÀçÁú

  • À¯¸®
  • ÇÃ¶ó½ºÆ½

¹è·² è¹ö ¼ö

  • ½Ì±Û è¹ö
  • µà¾ó è¹ö

¾àÁ¦ ºÐÀÚ

  • »ý¹°Á¦Á¦
  • ÀúºÐÀÚ

»ç¾÷ ±Ô¸ð

  • »ó¾÷
  • ÀüÀÓ»ó/ÀÓ»ó

ÁÖ¿ä Áö¿ª

  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç

ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish Á¦Á¶ ½ÃÀå : ¼ºÀå°ú µ¿Çâ

±âº»ÀûÀ¸·Î ÇÁ¸®ÇÊµå ½Ã¸°Áö´Â ¹Ì¸® ÃøÁ¤µÈ ¾çÀÇ ÁÖ»ç¾àÀ» ´ãÀº 1ȸºÐ ¾àǰÀÔ´Ï´Ù. ÁÖ»çÁ¦ ¹× ¹é½ÅÀÇ ÁÖ¿ä ¾àǰ ¿ë±â·Î »ç¿ëµË´Ï´Ù. ÇÁ¸®ÇÊµå ½Ã¸°Áö¿¡ ä¿öÁö´Â ¾à¹°ÀÇ ¹üÁÖ¿¡´Â Ç÷¾× ÀÚ±ØÁ¦, ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾ Á¦Á¦, ÀÎÅÍÆä·Ð, Ä¡·á¿ë ´Ü¹éÁú µîÀÌ ÀÖ½À´Ï´Ù. Áö³­ 10³âµ¿¾È ºñ°æ±¸ ÀǾàǰÀÇ °³¹ßÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÇÁ¸®ÇÊµå ½Ã¸°Áö »ç¿ë·®ÀÌ 3 ¹è Áõ°¡Çß½À´Ï´Ù. ƯÈ÷ ÀÌ·¯ÇÑ ÇÁ¸®ÇÊµå ½Ã¸°Áö´Â ±âÁ¸ÀÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ(¹ÙÀ̾Ë, ÁÖ»ç±â µî)¿¡ ºñÇØ Åõ¾à ½Ç¼ö °¡´É¼º °¨¼Ò, ȯÀÚ ¼øÀÀµµ Çâ»ó, ¹Ì»ý¹° ¿À¿° À§Çè °¨¼Ò µî ¿©·¯ °¡Áö ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ±× °á°ú, ÇÁ¸®ÇÊµå ½Ã¸°Áö´Â ÁÖ»çÁ¦ Àü´Þ, ƯÈ÷ ¸¸¼ºÁúȯ(¹Ýº¹ÀûÀÎ ¾à¹° Åõ¿©°¡ ÇÊ¿äÇÑ)ÀÇ Ä¡·á¿¡ ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

Prefilled Syringe Fill Finish Manufacturing Market-IMG1

ÇÁ¸®ÇÊµå ½Ã¸°Áö°¡ Á¦°øÇÏ´Â ¿©·¯ °¡Áö ÀåÁ¡Àº ¼¿ÇÁ ¸ÞµðÄÉÀÌ¼Ç Áõ°¡ Ãß¼¼¿Í ÇÔ²² ÀÌ·¯ÇÑ Àåºñ¿Í °áÇÕµÈ ¸¹Àº ÀǾàǰÀÇ ½ÂÀÎÀ¸·Î À̾îÁ³°í, ±× °á°ú ÃæÀü/¸¶¹«¸® ÀÛ¾÷ÀÇ ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ»ç±â ÃæÀü·®ÀÇ ¸é¹ÐÇÑ ¸ð´ÏÅ͸µ ¹× °ü¸®¿¡ µû¸¥ ±â¼úÀû Àü¹® Áö½ÄÀÇ Çʿ伺 µî ¿©·¯ °¡Áö ¾÷¹«»óÀÇ ¹®Á¦·Î ÀÎÇØ ½ÃÀå¿¡¼­´Â ÇÁ¸®Çʵå ÁÖ»ç±â ÃæÀü ¹× ¸¶°¨ ÀÛ¾÷ÀÇ ¾Æ¿ô¼Ò½ÌÀ¸·Î ÀüȯÇÏ´Â Ãß¼¼°¡ ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ º¸´Ù ¾ÈÀüÇÏ°í »ç¿ëÇϱ⠽¬¿î Åõ¾à ±â¼ú¿¡ ´ëÇÑ ÇöÀç ¼ö¿ä¿Í ºñ¿ë Àý°¨ ¹× È¿À²¼º Çâ»óÀ» À§ÇÑ ¾÷°èÀÇ ³ë·ÂÀº ÇâÈÄ ÇÁ¸®ÇÊµå ½Ã¸°Áö ÃæÀü ¹× ¸¶°¨ Á¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish Á¦Á¶ ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

ÀÌ º¸°í¼­´Â ¼¼°è ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish Á¦Á¶ ½ÃÀåÀÇ ÇöȲÀ» Á¶»çÇÏ°í ¾÷°èÀÇ ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù. ÀÌ º¸°í¼­ÀÇ ÁÖ¿ä Á¶»ç °á°ú´Â ´ÙÀ½°ú °°½À´Ï´Ù.

  • Àü ¼¼°è¿¡¼­ 100°³ ÀÌ»óÀÇ È¸»ç°¡ ÇÁ¸®Çʵå ÁÖ»ç±â À§Å¹ Fill Finish ¼­ºñ½º¸¦ Á¦°øÇÑ´Ù°í ÁÖÀåÇϸç, ÀÌµé ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ Áß ¾à 50%°¡ 500¸í ÀÌ»óÀÇ Á÷¿øÀ» º¸À¯ÇÑ ´ë±â¾÷À̶ó°í ÇÕ´Ï´Ù.
  • ½ÃÀå »óȲÀº ÀÌ ºÐ¾ß¿¡¼­ ¸í¼ºÀ» ½×Àº ±â¾÷ÀÌ Á¸ÀçÇѴٴ Ư¡ÀÌ ÀÖÀ¸¸ç, ±× Áß »ó´ç¼ö´Â ´Ù¾çÇÑ »ç¾÷ ±Ô¸ð·Î »ç¾÷À» Àü°³ÇÏ°í ´Ù¾çÇÑ Áö¿ª¿¡ À§Ä¡Çϰí ÀÖ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù.
  • 55% ÀÌ»óÀÇ ±â¾÷ÀÌ ÀúºÐÀÚ ÀǾàǰ°ú »ý¹°Á¦Á¦ ¸ðµÎ¿¡ ´ëÇÑ Fill Finish ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, »ý¹°Á¦Á¦¸¸À» ´ë»óÀ¸·Î ÇÏ´Â ±â¾÷Àº 20% Á¤µµÀÔ´Ï´Ù.
  • °ø±Þ¸Á Àü¹ÝÀÇ ¿ª·®À» È®º¸ÇÏ°í °í°´ÀÇ ÁøÈ­ÇÏ´Â ´ÏÁî¿¡ ´ëÀÀÇϱâ À§ÇØ ´Ù¾çÇÑ ±Ô¸ðÀÇ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ±â¾÷ÀÌ ´Ù¾çÇÑ Áö¿ª¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù.
Prefilled Syringe Fill Finish Manufacturing Market-IMG2
  • AMRI, Catalent Biologics, Pierre Fabrre, Sandoz µî ¿©·¯ À§Å¹ ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ(¾à 60°³»ç)°¡ ÀÓ»ó ¹× »ó¾÷Àû ±Ô¸ð ¸ðµÎ¿¡¼­ ÃæÀü ¹× ¸¶¹«¸® ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù.
  • ¾÷°è ÀÌÇØ°ü°èÀÚ ´ëºÎºÐÀÌ ¼±Áø±¹¿¡ ±â¹ÝÀ» µÎ°í ÀÖÁö¸¸, Àεµ, ´ë¸¸, ¹æ±Û¶óµ¥½Ã µî ¾Æ½Ã¾Æ ±¹°¡µéÀÇ ÃæÁø/¸¶¹«¸® »ç¾÷ÀÌ ºÎ»óÇϰí ÀÖ½À´Ï´Ù.
  • ÃæÀü/¸¶¹«¸® ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ±âÁ¸ ¿ë·®°ú »ý»ê ´É·ÂÀ» ¾÷±×·¹À̵åÇϱâ À§ÇØ È®Àå ÇÁ·ÎÁ§Æ®¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
  • ¿¹»ó´ë·Î, ÇÁ¸®ÇÊµå ½Ã¸°Áö¿ë ÃæÁø/¸¶¹«¸® À§Å¹ ÀåºñÀÇ ´ëºÎºÐÀº ´ëÇü ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡ ¼ÓÇØ ÀÖÀ¸¸ç, Àü ¼¼°è »ç¿ë °¡´ÉÇÑ ÀåºñÀÇ ¾à 80%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
  • ÇÁ¸®Çʵå ÁÖ»ç±â Á¶ÇÕ Á¦Ç° °³¹ßÀÚ¸¦ Æò°¡ÇÑ °á°ú, À¯·´°ú ºÏ¹Ì°¡ ÃæÀü/¸¶¹«¸® ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô Áß¿äÇÑ Çù·Â ±âȸ°¡ ÀÖ´Â Áö¿ªÀ¸·Î ¹àÇôÁ³½À´Ï´Ù.
  • ¾à 70¿© °³ÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö°¡ ÁÖ¿ä ±â¾÷¿¡¼­ »ý»êµÇ°í ÀÖÀ¸¸ç, ´ëºÎºÐ À¯¸®¿Í ÇÃ¶ó½ºÆ½ Àç·á·Î ÁÖ»ç±â ¹è·²À» »ý»êÇÒ ¼ö ÀÖ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù.
  • ´Ü-Áß±âÀûÀ¸·Î ÀǾàǰ °³¹ß ±â¾÷º° ÃæÁø ¸¶¹«¸® ¾÷¹«ÀÇ ¾Æ¿ô¼Ò½ÌÀÌ Áö¼ÓµÇ¾î À§Å¹ ¼­ºñ½º ½ÃÀåÀÇ ¿¬Æò±Õ ¼ºÀå·üÀº 11.9%¸¦ »óȸÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • Àå±âÀûÀ¸·Î º¼ ¶§, ÇÁ¸®ÇÊµå ½Ã¸°Áö ÃæÀü ¹× ¸¶°¨ ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô ¿¹»óµÇ´Â ±âȸ´Â ´Ù¾çÇÑ À¯ÇüÀÇ ¹è·² è¹ö, »ç¾÷ ±Ô¸ð ¹× Áö¿ªÀû Áö¿ª¿¡ Àß ºÐ»êµÇ¾î ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
Prefilled Syringe Fill Finish Manufacturing Market-IMG3
  • ÇÁ¸®ÇÊµå ½Ã¸°Áö¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í »ç¿ëÀÚ Ä£È­ÀûÀÎ ½Ã½ºÅÛ¿¡ ´ëÇÑ °ü½ÉÀ¸·Î ÀÎÇØ ÇâÈÄ ¼ö³â°£ ½ÃÀå ±âȸ´Â ºü¸¥ ¼Óµµ·Î ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish Á¦Á¶ ½ÃÀåÀÇ Âü¿© ±â¾÷ ¿¹

  • Ajinomoto Bio-Pharma Services
  • AMRI
  • BioPharma Solutions
  • Emergent BioSolutions
  • Patheon(a Thermo Fisher Scientific Company)
  • Consort Medical
  • EVER Pharma
  • GlaxoSmithKline
  • IDT Biologika
  • Rentschler Biopharma
  • Siegfried
  • Vetter Pharma
  • Biocon
  • Intas Pharmaceuticals
  • Kemwell Biopharma
  • Square Pharmaceuticals.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

Á¦3Àå ¼­·Ð

  • éÅÍ °³¿ä
  • ÇÁ¸®ÇÊµå ½Ã¸°ÁöÀÇ ¼­·Ð
  • ÇÁ¸®ÇÊµå ½Ã¸°ÁöÀÇ Fill Finish ó¸®
  • ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish ½ÃÀåÀÇ ¼ºÀå¿äÀÎ
  • ¸ê±Õ ÁÖ»çÁ¦ÀÇ Fill Finish ¾÷¹« ¾Æ¿ô¼Ò½ÌÀÇ Çʿ伺
  • Fill Finish ¼­ºñ½º ¾Æ¿ô¼Ò½ÌÀÇ ÀÌÁ¡
  • Fill Finish ¾÷¹«ÀÇ ¾Æ¿ô¼Ò½Ì¿¡ ¼ö¹ÝÇÏ´Â ¸®½ºÅ©
  • Fill Finish ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¼±Åýà ÁÖ¿ä °í·Á »çÇ×

Á¦4Àå ½ÃÀå ±¸µµ

  • éÅÍ °³¿ä
  • ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ : ½ÃÀå ±¸µµ

Á¦5Àå ºÏ¹ÌÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ : ±â¾÷ °³¿ä

  • éÅÍ °³¿ä
  • Ajinomoto Bio-Pharma Services
  • AMRI
  • BioPharma Solutions
  • Emergent BioSolutions
  • Patheon

Á¦6Àå À¯·´ÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ : ±â¾÷ °³¿ä

  • éÅÍ °³¿ä
  • Consort Medical
  • EVER Pharma
  • GlaxoSmithKline
  • IDT Biologika
  • Rentschler Biopharma
  • Siegfried
  • Vetter Pharma

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ : ±â¾÷ °³¿ä

  • éÅÍ °³¿ä
  • Biocon
  • Intas Pharmaceuticals
  • Kemwell Biopharma
  • Square Pharmaceuticals

Á¦8Àå ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ : ÃÖ±Ù µ¿Çâ

  • éÅÍ °³¿ä
  • È®Àå ¸®½ºÆ®
  • ÆÄÆ®³Ê½Ê ¸ðµ¨
  • ÆÄÆ®³Ê½Ê°ú Çù¾÷ ¸®½ºÆ®

Á¦9Àå ¿ë·® ºÐ¼®

Á¦10Àå ¼ö¿ä ºÐ¼®

Á¦11Àå ¼ö¿ä¿Í °ø±ÞÀÇ Áö¿ªÀû Æò°¡

  • éÅÍ °³¿ä
  • ÀüÁ¦¿Í ÁÖ¿ä ÆÄ¶ó¹ÌÅÍ
  • ºÏ¹Ì¿¡¼­ ¼ö¿ä¿Í °ø±ÞÀÇ Æò°¡
  • À¯·´¿¡¼­ ¼ö¿ä¿Í °ø±ÞÀÇ Æò°¡
  • ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ¼ö¿ä¿Í °ø±ÞÀÇ Æò°¡

Á¦12Àå °¡´É¼º ÀÖ´Â ÆÄÆ®³Ê ºÐ¼®

Á¦13Àå ½ÃÀå ±Ô¸ðÀÇ Æò°¡¿Í ±âȸ ºÐ¼®

  • éÅÍ °³¿ä
  • ¿¹Ãø Á¶»ç ¹æ¹ý°ú ÁÖ¿ä ÀüÁ¦Á¶°Ç
  • ÇÁ¸®ÇÊµå ½Ã¸°Áö Fill Finish ¼­ºñ½º ½ÃÀå Àüü(-2035³â)

Á¦14Àå ÇâÈÄ ¼ºÀå ±âȸ

  • éÅÍ °³¿ä
  • ¼ºÀåÇÏ´Â ÁÖ»çÁ¦ ÆÄÀÌÇÁ¶óÀÎ
  • ÇÁ¸®ÇÊµå ½Ã¸°ÁöÀÇ Àαâ Áõ°¡
  • Fill Finish ¾÷¹«ÀÇ ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ ¼±È£µµÀÇ Áõ°¡
  • ¹«±Õ Fill Finish ±â¼úÀÇ Áøº¸
  • ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ±âȸÀÇ È®´ë

Á¦15Àå »ç·Ê ¿¬±¸ : ÇÁ¸®ÇÊµå ½Ã¸°Áö Á¦Á¶¾÷ü

  • éÅÍ °³¿ä
  • ÇÁ¸®ÇÊµå ½Ã¸°Áö : ÀÔ¼ö °¡´É/°³¹ßÁßÀÎ µð¹ÙÀ̽º ¸®½ºÆ®
  • ÇÁ¸®ÇÊµå ½Ã¸°Áö : Á¦Á¶¾÷ü ¸®½ºÆ®

Á¦16Àå °á·Ð

Á¦17Àå ÀÎÅÍºä ±â·Ï

Á¦18Àå ºÎ·Ï 1 : Ç¥Çü½Ä µ¥ÀÌÅÍ

Á¦19Àå ºÎ·Ï 2 : ±â¾÷ ¸®½ºÆ®

KSA 25.07.10

PREFILLED SYRINGE FILL FINISH MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global prefilled syringe fill finish manufacturing market valued at USD 931 million in the current year is anticipated to grow at a lucrative CAGR of 11.9% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Therapeutic Area

  • Blood Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology Disorders
  • Neurological Disorders
  • Autoimmune Disorders
  • Others

Type of Syringe Barrel Material

  • Glass
  • Plastic

Number of Barrel Chambers

  • Single Chamber
  • Dual Chamber

Type of Drug Molecule

  • Biologic
  • Small Molecule

Scale of Operation

  • Commercial
  • Preclinical / Clinical

Key Geographical Regions

  • North America
  • Europe
  • Asia- Pacific

PREFILLED SYRINGE FILL FINISH MANUFACTURING MARKET: GROWTH AND TRENDS

Fundamentally, a prefilled syringe is a single dose of medication, containing a pre-measured amount of injectable. It is used as a primary drug container for injectable drugs and vaccines. Some of the categories of drugs packaged in prefilled syringes include blood stimulants, erythropoietin products, interferons and therapeutic proteins. Over the past ten years, with the increase in development of parenteral drugs, the usage of prefilled syringes has tripled. Notably, these prefilled syringes offer several advantages over traditional drug delivery systems (such as vials and syringes), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. As a result, prefilled syringes are preferably being used in the delivery of injectable drugs, especially in the treatment of chronic diseases (requiring repeated administration of the medications).

Prefilled Syringe Fill Finish Manufacturing Market - IMG1

The numerous benefits offered by prefilled syringes, coupled with the growing self-medication trend, have led to the approval of a number of drugs in combination with such devices, resulting in an increase in need to outsource fill / finish operations. Moreover, owing to a number of operational challenges, such as the requirement of technical expertise associated with close monitoring and control of syringe fill volume, the market has witnessed a shift in trend towards outsourcing of the fill / finish operations for prefilled syringes. Additionally, the current demand for safer, easier to use administration technologies along with the industry's efforts to reduce costs and increase efficiency are expected to drive the growth of the prefilled syringe fill finish manufacturing market in future.

PREFILLED SYRINGE FILL FINISH MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the global prefilled syringe fill finish manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Over 100 companies across the globe claim to provide contract fill / finish services for prefilled syringes; close to 50% of these service providers are large companies with over 500 employees.
  • The market landscape features the presence of well-established players in the domain, most of which claim to operate at various scales of operation and are located in different geographies.
  • Over 55% of the companies have the capabilities to offer fill / finish services for both small molecules and biologics; ~20% of the companies are offering these services for only biologics.
  • In order to acquire competencies across the supply chain and cater to the evolving needs of clients, companies offering services across different scales of operation have established presence in various geographies.
Prefilled Syringe Fill Finish Manufacturing Market - IMG2
  • Several contract service providers (~60), including AMRI, Catalent Biologics, Pierre Fabrre and Sandoz offer fill / finish services at both clinical and commercial scale of operation.
  • Although most industry stakeholders are based in the developed regions, fill / finish operations in Asian countries, such as India, Taiwan and Bangladesh, are emerging.
  • Fill / finish service providers are actively investing in expansion projects to upgrade existing capabilities and capacity; several partnerships, mostly focused on offering contract services, have also been forged.
  • As expected, majority of the installed contract fill / finish capacity for prefilled syringes belongs to the large service providers, accounting for around 80% of the available global capacity.
  • An evaluation of prefilled syringe combination product developers revealed that Europe and North America have emerged as the key regions for partnering opportunities for fill / finish service providers.
  • Around 70 prefilled syringes are being manufactured by large companies, most of which claim to be capable of fabricating syringe barrels from both glass and plastic materials.
  • We expect drug developers to continue to outsource their fill / finish operations in the short to midterm, resulting in an annualized growth at the rate of over 11.9% within the contract services market.
  • In the long-term, the projected opportunity for the fill / finish service providers for prefilled syringes is likely to be well distributed across various types of barrel chambers, scales of operation and geographical regions.
Prefilled Syringe Fill Finish Manufacturing Market - IMG3
  • With an increasing demand for prefilled syringes and focus on user-friendly systems, the market opportunity is projected to evolve at a rapid pace in the coming years.

Example Players in the Prefilled Syringe Fill Finish Manufacturing Market

  • Ajinomoto Bio-Pharma Services
  • AMRI
  • BioPharma Solutions
  • Emergent BioSolutions
  • Patheon (a Thermo Fisher Scientific Company)
  • Consort Medical
  • EVER Pharma
  • GlaxoSmithKline
  • IDT Biologika
  • Rentschler Biopharma
  • Siegfried
  • Vetter Pharma
  • Biocon
  • Intas Pharmaceuticals
  • Kemwell Biopharma
  • Square Pharmaceuticals.

PREFILLED SYRINGE FILL FINISH MANUFACTURING MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the prefilled syringe fill finish manufacturing market, focusing on key market segments, including [A] type of therapeutic area, [B] type of syringe barrel material, [C] number of barrel chambers, [D] type of drug molecule, [E] scale of operation and [F] key geographical regions.
  • Market Landscape: A comprehensive evaluation of companies offering contract fill / finish services for prefilled syringes, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] scale of operation, [D] location of the headquarters, [E] location of fill / finish facilities, [F] type of drug molecule, [G] syringe barrel material, [H] syringe fill volume and additional services offered and [I] installed capacity.
  • Company Profiles: In-depth profiles of the players engaged in this domain, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio, [D] fill / finish facilities and [E] recent developments and an informed future outlook.
  • Recent Developments: A comprehensive competitive analysis of recent developments pertaining to contract fill / finish services, based on various parameters, such as [A] year of development, [B] type of activity / development, [C] scale of operation of the project, [D] location of expanded facility, [E] type of drug molecule involved and [F] additional services offered.
  • Capacity Analysis: An in-depth analysis of contract fill / finish capacity of prefilled syringes, examining factors, such as [A] company size of manufacturer, [B] scale of operation, [C] location of headquarters and fill / finish facilities and [D] type of drug molecule.
  • Demand Analysis: A detailed analysis of the current and future demand for fill / finish of prefilled syringes, based on various parameters, such as [A] marketed drugs available, [B] target patient population, [C] dosing frequency, [D] dose strength, [E] geography, [F] type of drug molecule, [G] therapeutic area, [H] syringe barrel material and [I] number of barrel chambers.
  • Geographical Assessment of Demand and Supply: An insightful geographical analysis of demand and supply, based on several parameters, such as [A] number of prefilled syringe combination product developers, [B] number of prefilled syringe manufacturers, [C] number of prefilled syringe fill / finish service providers, [D] number of prefilled syringe fill / finish facilities, and [E] capacity and demand for prefilled syringes in that particular geographical region.
  • Likely Partner Analysis: A detailed analysis of the potential strategic partners for prefilled syringe fill / finish service providers, based on various parameters, such as [A] developer strength, [B] pipeline strength, [C] type of drug molecule, [D] target therapeutic area and [E] location of the headquarters of the company.
  • Case Study 1: A detailed discussion on the potential areas of growth, such as [A] growing injectable drugs pipeline, [B] increasing popularity of prefilled syringes, [C] rise in preference for outsourcing of fill / finish operations, [D] technological advancements in aseptic fill / finish processes and [E] growing opportunities in the Asia-Pacific region.
  • Case Study 2: Elaborate assessment of prefilled syringe manufacturers landscape, based on a number of relevant parameters, such as [A] syringe barrel material, [B] number of barrel chambers, [C] type of needle system, [D] barrel volume, [E] year of establishment and [F] location of the headquarters of manufacturers.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Prefilled Syringes
    • 3.2.1. Classification of Prefilled Syringes
    • 3.2.2. Manufacturing of Prefilled Syringes
    • 3.2.3. Advantages of Prefilled Syringes
      • 3.2.3.1. Benefits to Healthcare Professionals and End Users
      • 3.2.3.2. Benefits to Manufacturers
  • 3.3. Fill / Finish Processing of Prefilled Syringes
    • 3.3.1. Steps Involved in Fill / Finish Process
    • 3.3.2. Methods of Filling and Stoppering of Prefilled Syringes
    • 3.3.3. Prefilled Syringe Filling Technologies
  • 3.4. Factors Contributing to the Growth of Prefilled Syringe Fill / Finish Market
  • 3.5. Need for Outsourcing Fill / Finish Operations of Sterile Injectables
  • 3.6. Advantages of Outsourcing Fill / Finish Services
  • 3.7. Risks Associated with Outsourcing of Fill / Finish Operations
  • 3.8. Key Considerations While Selecting a Fill / Finish Service Provider

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Prefilled Syringe Fill / Finish Service Providers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Scale of Operation
    • 4.2.4. Analysis by Location of Headquarters
    • 4.2.5. Analysis by Location of Prefilled Syringe Fill / Finish Facilities
    • 4.2.6. Analysis by Type of Drug Molecule
    • 4.2.7. Analysis by Syringe Barrel Material
    • 4.2.8. Analysis by Syringe Fill Volume
    • 4.2.9. Analysis by Additional Services Offered
    • 4.2.10. Heat Map: Analysis by Company Size and Location of Headquarters
    • 4.2.11. Logo Landscape: Analysis by Company Size and Type of Drug Molecule
    • 4.2.12. Geographical Map: Analysis by Scale of Operation and Location of Fill / Finish Facilities
    • 4.2.13. Grid Representation: Distribution by Year of Establishment, Company Size and Type of Drug Molecule

5. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Ajinomoto Bio-Pharma Services
    • 5.2.1. Company Overview
    • 5.2.2. Recent Developments and Future Outlook
  • 5.3. AMRI
    • 5.3.1. Company Overview
    • 5.3.2. Recent Developments and Future Outlook
  • 5.4. BioPharma Solutions
    • 5.4.1. Company Overview
    • 5.4.2. Recent Developments and Future Outlook
  • 5.5. Emergent BioSolutions
    • 5.5.1. Company Overview
    • 5.5.2. Recent Developments and Future Outlook
  • 5.6. Patheon (a Thermo Fisher Scientific Company)
    • 5.6.1. Company Overview
    • 5.6.2. Recent Developments and Future Outlook

6. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN EUROPE: COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Consort Medical
    • 6.2.1. Company Overview
    • 6.2.2. Recent Developments and Future Outlook
  • 6.3. EVER Pharma
    • 6.3.1. Company Overview
    • 6.3.2. Recent Developments and Future Outlook
  • 6.4. GlaxoSmithKline
    • 6.4.1. Company Overview
    • 6.4.2. Recent Developments and Future Outlook
  • 6.5. IDT Biologika
    • 6.5.1. Company Overview
    • 6.5.2. Recent Developments and Future Outlook
  • 6.6. Rentschler Biopharma
    • 6.6.1. Company Overview
    • 6.6.2. Recent Developments and Future Outlook
  • 6.7. Siegfried
    • 6.7.1. Company Overview
    • 6.7.2. Recent Developments and Future Outlook
  • 6.8. Vetter Pharma
    • 6.8.1. Company Overview
    • 6.8.2. Recent Developments and Future Outlook

7. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC: COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Biocon
    • 7.2.1. Company Overview
    • 7.2.2. Recent Developments and Future Outlook
  • 7.3. Intas Pharmaceuticals
    • 7.3.1. Company Overview
    • 7.3.2. Recent Developments and Future Outlook
  • 7.4. Kemwell Biopharma
    • 7.4.1. Company Overview
    • 7.4.2. Recent Developments and Future Outlook
  • 7.5. Square Pharmaceuticals
    • 7.5.1. Company Overview
    • 7.5.2. Recent Developments and Future Outlook

8. PREFILLED SYRINGE FILL / FINISH SERVICE PROVIDERS: RECENT DEVELOPMENTS

  • 8.1. Chapter Overview
  • 8.2. List of Expansions
    • 8.2.1. Analysis by Year of Expansion
    • 8.2.2. Analysis by Type of Expansion
    • 8.2.3. Analysis by Expanded Scale of Operation
    • 8.2.4. Analysis by Location of Expansion Project
    • 8.2.5. Analysis by Type of Drug Molecule Involved
    • 8.2.6. Analysis by Additional Services Offered (Expansion Specific)
  • 8.3. Partnership Models
  • 8.4. List of Partnerships and Collaborations
    • 8.4.1. Analysis by Year of Partnership
    • 8.4.2. Analysis by Type of Partnership
    • 8.4.3. Analysis by Scale of Operation (Deal Specific)
    • 8.4.4. Analysis by Additional Services Offered (Deal Specific)

9. CAPACITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Methodology
  • 9.3. Global, Prefilled Syringe Fill / Finish Capacity (by Number of Units)
    • 9.3.1. Analysis by Company Size
    • 9.3.2. Analysis by Scale of Operation
    • 9.3.3. Analysis by Location of Headquarters
    • 9.3.4. Analysis by Location of Fill / Finish Facilities
    • 9.3.5. Analysis by Type of Drug Molecule
  • 9.4. Global, Prefilled Syringe Fill / Finish Capacity (by Volume)
    • 9.4.1. Analysis by Company Size (Manufacturer)
    • 9.4.2. Analysis by Scale of Operation
    • 9.4.3. Analysis by Location of Headquarters
    • 9.4.4. Analysis by Location of Fill / Finish Facilities
    • 9.4.5. Analysis by Type of Drug Molecule

10. DEMAND ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Assumptions and Methodology
  • 10.3. Global Demand for Prefilled Syringes Fill / Finish Services
    • 10.3.1. Global Demand for Commercialized Prefilled Syringes Fill / Finish Services
      • 10.3.1.1. Analysis by Geography
        • 10.3.1.1.1. North America
        • 10.3.1.1.2. Europe
        • 10.3.1.1.3. Asia-Pacific
        • 10.3.1.1.4. Latin America
        • 10.3.1.1.5. Middle East and Africa
      • 10.3.1.2. Analysis by Syringe Barrel Material
      • 10.3.1.3. Analysis by Number of Barrel Chambers
      • 10.3.1.4. Analysis by Type of Drug Molecule
      • 10.3.1.5. Analysis by Therapeutic Area
      • 10.3.1.6. Analysis by Specialty Syringes
    • 10.3.2. Global Demand for Clinical Prefilled Syringes Fill / Finish Services
  • 10.4. Demand and Supply Analysis
    • 10.4.1. Demand and Supply Analysis (Scenario 1)
    • 10.4.2. Demand and Supply Analysis (Scenario 2)
    • 10.4.3. Demand and Supply Analysis (Scenario 3)

11. GEOGRAPHICAL ASSESSMENT OF DEMAND AND SUPPLY

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Key Parameters
  • 11.3. Demand and Supply Assessment in North America
    • 11.3.1. Key Geographies
      • 11.3.1.1. US
  • 11.4. Demand and Supply Assessment in Europe
    • 11.4.1. Key Geographies
      • 11.4.1.1. France
      • 11.4.1.2. Germany
      • 11.4.1.3. Italy
  • 11.5. Demand and Supply Assessment in Asia-Pacific Region
    • 11.5.1. Key Geographies
      • 11.5.1.1. India
      • 11.5.1.2. Japan

12. LIKELY PARTNER ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Methodology and Key Parameters
  • 12.3. Likely Partner Analysis
    • 12.3.1. Opportunities in North America
      • 12.3.1.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
      • 12.3.1.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers
    • 12.3.2. Opportunities in Europe
      • 12.3.2.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
      • 12.3.2.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers
    • 12.3.3. Opportunities in Asia-Pacific and Rest of the World
      • 12.3.3.1. Most Likely Partners for Prefilled Syringe Fill / Finish Service Providers
      • 12.3.3.2. Likely Partners for Prefilled Syringe Fill / Finish Service Providers

13. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall Prefilled Syringe Fill / Finish Services Market, Till 2035
    • 13.3.1. Prefilled Syringe Fill / Finish Services Market: Distribution by Scale of Operation, Till 2035
    • 13.3.2. Prefilled Syringe Fill / Finish Services Market: Distribution by Geographical Region
      • 13.3.2.1. Prefilled Syringe Fill / Finish Services Market in North America
      • 13.3.2.2. Prefilled Syringe Fill / Finish Services Market in Europe
      • 13.3.2.3. Prefilled Syringe Fill / Finish Services Market in Asia-Pacific
      • 13.3.2.4. Prefilled Syringe Fill / Finish Services Market Latin America
      • 13.3.2.5. Prefilled Syringe Fill / Finish Services Market in Middle East and Africa
    • 13.3.3. Prefilled Syringe Fill / Finish Services Market: Distribution by Type of Drug Molecule, Till 2035
    • 13.3.4. Prefilled Syringe Fill / Finish Services Market: Distribution by Therapeutic Area
    • 13.3.5. Prefilled Syringe Fill / Finish Services Market: Distribution by Syringe Barrel Material, Till 2035
    • 13.3.6. Prefilled Syringe Fill / Finish Services Market: Distribution by Number of Barrel Chambers, Till 2035

14. FUTURE GROWTH OPPORTUNITIES

  • 14.1. Chapter Overview
  • 14.2. Growing Injectable Drugs Pipeline
  • 14.3. Increase in Popularity of Prefilled Syringes
  • 14.4. Rise in Preference for Outsourcing Fill / Finish Activities
  • 14.5. Advances in Aseptic Fill / Finish Technologies
  • 14.6. Growing Opportunities in the Asia-Pacific Region

15. CASE STUDY: PREFILLED SYRINGE MANUFACTURERS

  • 15.1. Chapter Overview
  • 15.2. Prefilled Syringes: List of Available / Under Development Devices
    • 15.2.1. Analysis by Syringe Barrel Material
    • 15.2.2. Analysis by Number of Barrel Chambers
    • 15.2.3. Analysis by Type of Needle System
    • 15.2.4. Analysis by Barrel Volume
  • 15.3. Prefilled Syringes: List of Manufacturers
    • 15.3.1. Analysis by Year of Establishment
    • 15.3.2. Analysis by Location of Headquarters

16. CONCLUDING REMARKS

  • 16.1. Chapter Overview
  • 16.2. Key Takeaways

17. INTERVIEW TRANSCRIPTS

  • 17.1. Chapter Overview
  • 17.2. Company A
    • 17.2.1. Company Snapshot
    • 17.2.2. Interview Transcript: President and Cofounder
  • 17.3. Company B
    • 17.3.1. Company Snapshot
    • 17.3.2. Interview Transcript: Chief Technical Officer
  • 17.4. Company C
    • 17.4.1. Company Snapshot
    • 17.4.2. Interview Transcript: Chief Commercial Officer
  • 17.5. Company D
    • 17.5.1. Company Snapshot
    • 17.5.2. Interview Transcript: Associate Director, Head of Process Sciences Formulation and Fill / Finish
  • 17.6. Company E
    • 17.6.1. Company Snapshot
    • 17.6.2. Interview Transcript: Research Director and Head of Formulation Development
  • 17.7. Company F
    • 17.7.1. Company Snapshot
    • 17.7.2. Interview Transcript: Design Director

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦